American Society for Transplantation and Cellular Therapy Series: #3—Prevention of Cytomegalovirus Infection and Disease After Hematopoietic Cell Transplantation

• Published in: Transplantation and cellular therapy Vol. 27; no. 9; pp. 707 - 719
• Main Authors: Hakki, Morgan, Aitken, Samuel L., Danziger-Isakov, Lara, Michaels, Marian G., Carpenter, Paul A., Chemaly, Roy F., Papanicolaou, Genovefa A., Boeckh, Michael, Marty, Francisco M.
• Format: Journal Article
• Language: English
• Published: Elsevier Inc 01.09.2021
• Subjects: Cytomegalovirus; Guideline; Hematopoietic cell transplant; Preemptive therapy; Prevention; Prophylaxis; Prevention; Cytomegalovirus; Guideline; Hematopoietic cell transplant; Prophylaxis; Preemptive therapy
• ISSN: 2666-6367; 2666-6367
• DOI: 10.1016/j.jtct.2021.05.001

The Practice Guidelines Committee of the American Society for Transplantation and Cellular Therapy partnered with its Transplant Infectious Disease Special Interest Group to update its 2009 compendium-style infectious diseases guidelines for the care of hematopoietic cell transplant (HCT) recipients. A new approach was taken with the goal of better serving clinical providers by publishing each standalone topic in the infectious disease series as a concise format of frequently asked questions (FAQ), tables, and figures. Adult and pediatric infectious disease and HCT content experts developed and answered FAQs. Topics were finalized with harmonized recommendations that were made by assigning an A through E strength of recommendation paired with a level of supporting evidence graded I through III. The third topic in the series focuses on the prevention of cytomegalovirus infection and disease in HCT recipients by reviewing prophylaxis and preemptive therapy approaches; key definitions, relevant risk factors, and diagnostic monitoring considerations are also reviewed.